Updated:
Atea Pharmaceuticals
Atea Pharmaceuticals was established in 2013 by Jean-Pierre Sommadossi, a virologist with four decades of drug-development experience, most notably as...
Atea Pharmaceuticals
Atea Pharmaceuticals was established in 2013 by Jean-Pierre Sommadossi, a virologist with four decades of drug-development experience, most notably as founder and CEO of Idenix Pharmaceuticals. The company emerged from a collaboration with Roche to develop nucleotide prodrugs for hepatitis C, building a pipeline of orally administered antiviral candidates before pivoting to pandemic-responsive programs. Sommadossi's scientific lineage traces through Emory University and the discovery of sofosbuvir's chemical precursors — an intellectual foundation that shapes the firm's core chemistry. The company's strategy centers on purine nucleotide prodrugs designed to inhibit the viral RNA-dependent RNA polymerase. Lead asset bemnifosbuvir, an oral antiviral targeting SARS-CoV-2, entered Phase 3 trials for high-risk outpatients in partnership with Roche. The global SUNRISE-3 trial enrolled over 2,200 participants across North America, Europe, Asia, and Latin America. A prior Phase 2 candidate, AT-527, failed to meet its primary endpoint in the MORNINGSKY trial in 2021, prompting a strategic reset. Atea's pipeline also includes AT-752 for dengue fever — a flavivirus with no approved antiviral — and earlier-stage compounds for hepatitis C. The firm has disclosed collaborations with the Biomedical Advanced Research and Development Authority and maintains a co-development agreement with Roche for SARS-CoV-2 indications outside the United States. Atea operates from a single headquarters in Boston, having reduced headcount from over 100 to roughly 60 full-time employees in a restructuring following the 2021 clinical setback. The firm held approximately $600 million in cash and marketable securities at year-end 2022, a balance sheet that funds operations into 2026 without requiring near-term capital raises. Its board includes representatives from Bain Capital Life Sciences and other crossover investors who backed the company before its public listing. October 2023: Announced that the SUNRISE-3 trial of bemnifosbuvir did not meet its primary endpoint of reducing time to symptom resolution, triggering a further strategic review by management. Atea combines a public-market funding structure with the pipeline concentration of a private, founder-led research organization — an unusual posture for a clinical-stage antiviral developer. Sommadossi holds multiple executive roles as CEO, chairman, and president, concentrating scientific and operational authority under a single decision-maker. The firm's partnership with Roche on global development and commercialization provides distribution infrastructure while limiting Atea's revenue share on partnered indications. This hybrid model — publicly traded, partnership-dependent, founder-controlled — creates a governance structure that differs markedly from both traditional biotech portfolio companies and larger diversified pharmaceutical firms.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Jean-Pierre Sommadossi
Chief Executive Officer & Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Atea Pharmaceuticals?
Jean-Pierre Sommadossi serves as Chief Executive Officer, Chairman, and President, concentrating strategic, scientific, and capital-allocation authority. Atea operates as an operating company, not an investment fund, so capital deployment decisions center on clinical-trial funding and partnership structuring rather than portfolio construction. The board includes representatives from Bain Capital Life Sciences and other institutional investors who influence major financing and partnership decisions.
How does Atea Pharmaceuticals source its drug candidates?
Atea develops antiviral candidates through internal medicinal chemistry targeting the viral RNA polymerase, a mechanism the founding team advanced at Idenix Pharmaceuticals. The firm's purine nucleotide prodrug platform generates analogs of adenosine and guanosine that incorporate preferentially into viral RNA, causing chain termination. This in-house discovery capability distinguishes Atea from companies that in-license late-stage assets, though the Roche partnership covers certain clinical development and commercialization activities.
Is Atea Pharmaceuticals a family office or an asset manager?
No. Atea Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company listed on Nasdaq under the ticker AVIR. It develops antiviral therapeutics rather than managing capital for third parties. The firm's classification in Altss reflects its institutional-investor ownership profile and crossover-fund backing, not family-office structure.
What happened to Atea's COVID-19 antiviral program?
Atea's lead COVID-19 candidate, bemnifosbuvir, failed its Phase 3 SUNRISE-3 trial in October 2023, missing the primary endpoint of reduced time to symptom resolution in high-risk outpatients. An earlier Phase 2 candidate, AT-527, had missed its primary endpoint in the MORNINGSKY trial in October 2021. As of early 2024, the firm was evaluating strategic options for the COVID-19 program while advancing its dengue and hepatitis C pipeline assets.
Does Atea have any other programs beyond COVID-19?
Yes. Atea is developing AT-752 for dengue fever, a mosquito-borne flavivirus with no approved antiviral therapy. The compound has completed Phase 1 testing. The firm also maintains earlier-stage hepatitis C virus programs targeting the viral polymerase, building on the scientific heritage Sommadossi established at Idenix. The Roche collaboration includes rights to certain non-COVID-19 indications.
How is Atea Pharmaceuticals funded?
Atea completed an initial public offering in October 2020, raising over $350 million, and entered 2023 with roughly $934 million in cash and marketable securities. The firm has historically been backed by crossover investors including Bain Capital Life Sciences. Its partnership with Roche provides milestone payments and cost-sharing for clinical development, reducing the burn rate on partnered programs.
What is Atea's relationship with Roche?
Atea and Roche entered a collaboration in 2020 granting Roche exclusive rights to develop and commercialize Atea's oral COVID-19 antiviral candidate outside the United States. Under the agreement, Atea retained full US rights and received an upfront payment. The partnership structured shared clinical development costs and tiered royalties, with Roche assuming primary commercial responsibility in its territories.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: